Exelixis
EXEL
#2109
Rank
NZ$12.18 B
Marketcap
$42.70
Share price
-1.53%
Change (1 day)
18.19%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of June 2024 : NZ$3.42 B

According to Exelixis's latest financial reports the company has NZ$3.42 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$NZ$3.57 B-8.66%
2022-12-31$NZ$3.91 B21.42%
2021-12-31$NZ$3.22 B23.54%
2020-12-31$NZ$2.61 B4.54%
2019-12-31$NZ$2.49 B30.28%
2018-12-31$NZ$1.91 B378.14%
2017-12-31$NZ$0.40 B211.17%
2016-12-31$NZ$0.12 B-162.61%
2015-12-31$-NZ$0.21 B40.71%
2014-12-31$-NZ$0.15 B-281.5%
2013-12-31$NZ$80.65 M-77.69%
2012-12-31$NZ$0.36 B211.36%
2011-12-31$NZ$0.11 B-139.08%
2010-12-31$-NZ$0.3 B30.85%
2009-12-31$-NZ$0.23 B132.85%
2008-12-31$-NZ$97.53 M-188.12%
2007-12-31$NZ$0.11 B-13.96%
2006-12-31$NZ$0.12 B53.43%
2005-12-31$NZ$83.82 M18.04%
2004-12-31$NZ$71.01 M-71.41%
2003-12-31$NZ$0.24 B-26.1%
2002-12-31$NZ$0.33 B-41.16%
2001-12-31$NZ$0.57 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
NZ$28.16 B 721.92%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$126.48 B 3,591.58%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$70.55 B 1,959.13%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$27.58 B 705.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$9.57 B 179.52%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$115.63 B 3,274.86%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$142.20 B 4,050.29%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$1.13 M-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$46.62 M-98.64%๐Ÿ‡บ๐Ÿ‡ธ USA